New findings from a landmark clinical trial show that although certain gene variants may predict whether a person is likely to develop age-related macular degeneration (AMD), a potentially blinding eye disease that afflicts more than nine million Americans, these genes do not predict how patients will respond to Lucentis™ and Avastin™, the two medications most widel…
Castle Biosciences launches MyUvealMelanoma website
Castle Biosciences Inc., a leading developer of prognostic tests for rare cancers, announced today the launch of MyUvealMelanoma.com, a website created to educate newly diagnosed patients, their families and healthcare providers about the most common f…
Adalimumab for the Treatment of Non-infectious Uveitis
Is adalimumab an effective and safe therapeutic option in the treatment of uveitis, even if patients were non-responsive to previous other anti-TNF therapy? The British Journal of Ophthalmology
Evaluation of Moxifloxacin 0.5% in Treatment of Nonperforated Bacterial Corneal Ulcers: A Randomized Controlled Trial – Corrected Proof
Purpose:
To compare the equivalence of moxifloxacin 0.5% with a combination of fortified cefazolin sodium 5% and tobramycin sulfate 1.3% eye drops in the treatment of moderate bacterial corneal ulcers.
Design:
Randomized, controlled, equivalence cl…
Predictive Value in Retinal Vein Occlusions of Early Versus Late or Incomplete Ranibizumab Response Defined by Optical Coherence Tomography – Corrected Proof
Purpose:
To determine if optical coherence tomography (OCT) at baseline or month 3 in the Treatment of Macular Edema following Branch Retinal Vein Occlusion: Evaluation of Efficacy and Safety (BRAVO) and Treatment of Macular Edema following Central Retinal Vein Occlusion: Evaluation of Efficacy and Safety (CRUISE) studies provides information that predicts visual outcome.
Design:
Post hoc analysis from 2 prospective, randomized, controlled clinical trials.
Participants:
Three hundred ninety-seven patients from the BRAVO study and 392 patients from the CRUISE study.
Methods:
Time-domain OCT imaging data were analyzed.
Main Outcome Measures:
Mean change from baseline best-corrected visual acuity (BCVA) letter score (Read more...)
Body Stature Growth Trajectories during Childhood and the Development of Myopia – Corrected Proof
Purpose:
Stature at a particular age can be considered the cumulative result of growth during a number of preceding growth trajectory periods. We investigated whether height and weight growth trajectories from birth to age 10 years were related to refractive error at ages 11 and 15 years, and eye size at age 15 years.
Design:
Prospective analysis in a birth cohort.
Participants:
Children participating in the Avon Longitudinal Study of Parents and Children (ALSPAC) U.K. birth cohort (minimum N = 2676).
Methods:
Growth trajectories between birth and 10 years were modeled from a series of height and weight measurements (N (Read more...)